A new drug treatment for Parkinson's, opicapone, has launched in the UK. It could prolong the effect of levodopa and reduce the number of tablets required.
We're delighted to announce that the European Medicines Agency (EMA) is officially supporting the use of a particular type of brain scan to help people in the earliest stages of Parkinson's to participate in clinical trials.
New research published in the journal ACS Chemical Neuroscience has identified caffeine-like compounds that may tackle the underlying causes of Parkinson's.
BBC Two programme 'Nature's Weirdest Events' will feature a Parkinson's UK study into whether skin odour can lead to early diagnosis of Parkinson's.
New research shows that people recently diagnosed with Parkinson's who are at high or medium risk of cardiovascular disease tend to have more problems with walking and memory.
A new clinical study published in the journal Parkinsonism and Related Disorders links higher caffeine consumption to slower development of Parkinson's symptoms after diagnosis.
Parkinson's UK is at the World Parkinson Congress 2016 in Portland, Oregon to share experiences and learn about the latest Parkinson's research and thinking.
The Association of Medical Research Charities has launched a new booklet about using health information which includes a case study from Parkinson's UK.
Proteins involved in protecting connections between nerve cells may play a role in memory problems that affect people with conditions like Parkinson's.